Background and study aim: Major changes have emerged during the last few years in the treatment of chronic HCV infection. Several direct acting antiviral agents (DAAs) have been developed showing potent activity with higher rates of sustained virological response. This study shows comparison between triple therapy regimen (Peginterferon/ Ribavirin/ Sofosbuvir) and dual therapy regimen (Simprevir/Sofosbuvir) concerning efficacy and safety for Egyptian patients with chronic HCV infection.
Background and study aim: Major changes have emerged during the last few years in the treatment of chronic HCV infection. Several direct acting antiviral agents (DAAs) have been developed showing potent activity with higher rates of sustained virological response. This study shows comparison between triple therapy regimen (Peginterferon/ Ribavirin/ Sofosbuvir) and dual therapy regimen (Simprevir/Sofosbuvir) concerning efficacy and safety for Egyptian patients with chronic HCV infection.
Patients and Methods:
This retrospective comparative study included 500 Egyptian patients with chronic HCV infection, randomly selected from BeniSuef centre of treatment of viral hepatitis affiliated to the National committee for control of viral hepatitis (NCCVH). They were classified into two groups; triple therapy group included 250 patients had received pegylated interferon alpha, ribavirin and sofosbuvir for 12 weeks and dual therapy group included 250 patients had received sofosbuvir and simeprevir for 12 weeks. All patients were monitored for treatment safety and efficacy.
Results:
In the triple therapy group, mostly observed clinical side effects were; flu like illness (40% of patients), GI manifestations (20.8% of patients) and psychological manifestations (10.4% of patients) while photosensitivity (22% of patients), flu like illness (18.8% of patients) and GI manifestations (4.8% of patients) were the most frequently occurring clinical adverse effects in dual therapy group. Anemia (62.4% of patients) and leucopenia (49.6% of patients) were the mostly observed hematological abnormalities in triple therapy group while hyperbilirubinemia (38% of patients) was the mainly observed biochemical abnormality in dual therapy group. In the triple therapy group, the end of treatment response (ETR) rate was 95.6% while sustained virological response (SVR) rate was 91.2%. In dual therapy group, ETR rate was 95.6 % while SVR rate was 93.6 %.
Conclusion:
The dual therapy (Simeprevir and Sofosbuvir) regimen is more tolerated than triple therapy (Peginterferon, Ribavirin and Sofosbuvir) regimen for Egyptian patients with chronic HCV infection. There was no statistically significant difference as regard sustained virological response between both triple therapy and dual therapy regimens. This study evaluates the efficacy and safety of both regimens in treatment of Egyptian patients with chronic HCV infection.
Abbreviations

PATIENTS AND METHODS
This non-interventional, retrospective comparative study includes 500 Egyptian patients with chronic HCV infection randomly selected from Beni-Suef centre of treatment of viral hepatitis which is affiliated to the National committee for control of viral hepatitis (NCCVH) from October 2014 till November 2015.
Inclusion criteria  Patients with chronic HCV infection.
 Age between 18 -70 years old.
Exclusion criteria
 Patients with other causes of chronic liver disease were excluded (e.g. chronic HBV, confirmed autoimmune hepatitis, non alcoholic fatty liver disease, metabolic liver diseases).
 Patients with history of HCC or other malignancies.
 Alcohol consumption (>50 gm/day in men and 40 gm/day in women).
 Decompensated liver cirrhosis. HCV RNA is below the lower limit of detection at the end of treatment and after 12 weeks from end of treatment (SVR). -Treatment failure was defined as: -Viral non response: HCV RNA persistently above lower limit of detection at end of treatment -Viral Relapse was defined as confirmed HCV RNA above lower limit of detection during the follow up period for patients who achieved HCV RNA below lower limit of detection at the end of treatment.
The results were collected, arranged in tables and figures and statistically analyzed.
Statistical analysis:
Data were analyzed using the software, Statistical Package for Social Science (SPSS) version 20, then processed and tabulated. Frequency distribution with its percentage and descriptive statistics with mean values and standard deviation were calculated. Chi-square and t-test were done whenever needed. Probabilities of value (p value) of less than 0.05 were considered significant.
RESULTS
Age and sex:
The mean age of patients of triple therapy group was 49.2±10.5 years (135 males (54%) and 115 females (46%)) and the mean age of patients of dual therapy group was 52.6±12.1 years (104 males (41.6%) and 146 females (58.4%)).
Clinical adverse reactions:
Pruritus is present in 2.8% of cases in triple therapy group and absent in dual therapy group, photosensitivity in 22% of cases in dual therapy group and absent in triple therapy group, flu like illness in 40% of cases in triple therapy group versus 18.8% of cases in dual therapy group, GI manifestations in 20.8% of cases in triple therapy group versus 4.8% of cases in dual therapy group, psychological manifestations in 10.4% of cases in triple therapy group and absent in dual therapy group and hair loss in 2.8 % of cases in triple therapy group versus 0.4% of cases in dual therapy group). There was a statistically significant difference between both groups regarding recorded adverse effects (p<0.05) (Figure1).
Laboratory findings:
In triple therapy group, the mean hemoglobin level was 13.67 g/dl before treatment and 11.67 g/dl at the end of treatment with statistically significant decrease (p<0.05), the mean WBCs count was 6138.8 /mcl before treatment and 4149.2 /mcl at the end of treatment with statistically significant decrease (p<0.05) and the mean platelet count (*1000) was 183.8 /mcl before treatment and 164.2/mcl at the end of treatment with statistically significant decrease (p<0.05). In dual therapy group, the mean hemoglobin level was 12.7 g/dl before treatment and 12.74 g/dl at the end of treatment with statistically non significant increase, the mean WBCs count was 5612.2 /mcl before treatment and 5031/mcl at the end of treatment with statistically significant decrease (p<0.05) and the mean platelet count (*1000) was 155.4 /mcl before treatment and 166 /mcl at the end of treatment with statistically significant increase (p<0.05) ( Table 1 ).
In triple therapy group, anemia was observed in 13.2% of cases before treatment and in 62.4% of cases at the end of treatment, leucopenia was observed in 6.8% of cases before treatment and in 49.6% of cases at the end of treatment, but in dual therapy group, anemia was observed in 40.8% of cases before treatment and in 28% of cases at the end of treatment and leucopenia was observed in 16.4% of cases before treatment and in 12% of cases at the end of treatment.
There was significant decrease of mean serum AST and ALT levels among both triple therapy and dual therapy groups (mean serum AST in triple therapy group was 63.6 IU/L before starting treatment and 40.1 IU/L after 12 weeks from starting treatment and in dual therapy group it was 69.8 IU/L before starting treatment and 39.8 IU/L after 12 weeks from starting treatment and mean serum ALT in triple therapy group was 57 IU/L before starting treatment and 36.8 IU/L after 12 weeks from starting treatment and in dual therapy group it was 55.4 IU/L before starting treatment and 32.9 IU/L after 12 weeks from starting treatment) (p<0.05) ( Table 2 ).
In triple therapy group, the mean serum bilirubin was 0.8 mg/dl before treatment and 0.95 mg/dl at the end of treatment and in dual therapy group, it was 0.89 mg/dl before treatment and 1.37 mg/dl at the end of treatment with statistically significant increase in both groups (p<0.05) ( Table 2) . Hyperbilirubinemia in triple therapy group was observed in 3.2% of cases before treatment and in 7.2% of cases at the end of treatment while in dual therapy group, it was observed in 6% of cases before treatment and in 38% of cases at the end of treatment.
Virological response:
End of treatment response (ETR) was the same in both triple therapy and dual therapy groups (95.6%), but there was a non-statistically significant difference between both groups in sustained virological response (SVR) (91.2% of cases in triple therapy group versus 93.6% of cases in dual therapy group) (Figure2). In the present study, the mean hemoglobin level in triple therapy group was significantly decreased at the end of treatment (13.67 ± 1.42 g/dl before starting treatment) versus (11.67 ± 1.38 g/dl at the end of treatment). In the dual therapy group; the mean hemoglobin level was increased at the end of treatment (12.71 ±1.33 g/dl before starting treatment) versus (12.74 ± 1.27 g/dl at the end of treatment), but this increase wasn't statistically significant. The mean hemoglobin level at the end of treatment in dual therapy group was significantly higher than that in triple therapy group (12.74 ± 1.27 g/dl) versus (11.67 ± 1.38 g/dl) inspite of that the mean hemoglobin level was significantly higher in triple therapy group than dual therapy group before starting treatment (13.67 ± 1.42 g/dl) versus (12.74 ± 1.27 g/dl). These data clarify that triple therapy regimen has a negative effect on hemoglobin level compared to dual therapy regimen.
The mean WBCs count in both triple therapy and dual therapy group was significantly reduced at the end of treatment; (6138.8±1775.3/mcl before treatment) versus (4149.2 ± 1243/mcl at the end of treatment) and (5612.2 ± 1817/mcl before treatment) versus (5031 ± 1265.6/mcl at the end of treatment) respectively. The mean WBCs count at the end of treatment in dual therapy group was significantly higher than that in triple therapy group (5031±1265.6/mcl) versus (4149.2±1243 /mcl) inspite of that the mean WBCs count was significantly higher in triple therapy group than dual therapy group before starting treatment (5612.2±1817/mcl) versus (6138.8±1775.3 /mcl).
The mean platelet count (*1000) in triple therapy group was significantly decreased at the end of treatment (183.8 ± 51.1 /mcl before treatment) versus (164.2 ± 43 /mcl at the end of treatment). In dual therapy group; the mean platelet count (*1000) was significantly increased at the end of treatment (155.4 ± 55.2 /mcl before treatment) versus 165.9 ± 55.2 /mcl at the end of treatment). These results indicate that triple therapy regimen has a negative effect on platelet count compared to dual therapy regimen. differ with the present study in the point of mean serum bilirubin which shows no statistically difference before starting treatment and at the end of treatment (0.89 ± 0.09 mg/dl before starting treatment) and (1.11 ± 0.14 mg/dl at the end of treatment) for patients received triple therapy regimen in their study [9].
In the present study in triple therapy group; anemia before treatment was detected in 13.2% versus 62.4% of cases at the end of treatment. These data nearly comes in accordance with Steinebrunner and others [6] who demonstrated that anemia was detected in 75% of cases received triple therapy regimen in their study [6] . But Lawitz and his colleagues [10] declared different results regarding percent of occurrence of anemia with triple therapy regimen; they figured that anemia had occurred in 23% of cases who received triple therapy regimen in their study.
In triple therapy group, Leucopenia in this study was detected before treatment in 6.8% versus 49.6% of cases at the end of treatment which comes in disagreement with Wehmeyer and other colleagues [11] who revealed that leucopenia was occurred in 12.5% of cases.
This relative disparity between results in this study and that of other studies may be due to difference in the cut off values (The cut off value of anemia in this study was (hemoglobin <11.5 g/dL) while in Lawitz and his colleagues [10] it was (hemoglobin <10 g/dL) and the cut off value of leucopenia in this study was (WBCs <4000 /mcl) but in Wehmeyer other colleagues [11] it was (WBCs <2000 /mcl).
In dual therapy group in the present study; anemia (hemoglobin <11.5 g/dL) before starting treatment was detected in 40.8% versus 28% of cases at the end of treatment and leucopenia was detected in 16.4% of cases before starting treatment versus 12% of cases at the end of treatment. This data comes in difference with Modi and others [8] who reported that anemia was recorded in 10% of cases received dual therapy regimen. Pearlman and others [5] also reported different results; they declared that anemia was recorded in 2% of cases in received dual therapy regimen [5, 8] . This relative disparity between the percent of anemia in this study and other studies may be explained by that in this study 40.8% of patients received dual therapy regimen were anemic before starting treatment. 
CONCLUSION
In Egyptian patients with chronic HCV infection who had been included in this study; the dual therapy regimen (Simeprevir/ Sofosbuvir) was more tolerated with less adverse effects than the triple therapy regimen (Pegylated interferon/ Ribavirin/ Sofosbuvir) apart from the occurrence of photosensitivity and mild hyperbilirubinemia in some of patients in dual therapy group. There was no statistical difference as regard sustained virological response between both triple therapy and dual therapy groups with slightly higher sustained virological response rates in dual therapy group than triple therapy group.
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